Genomic Health, Inc. (GHDX) Misses Q4 EPS by 2c, Offers FY12 Sales Guidance
Tweet
Share
E-mailGet Alerts GHDX Hot Sheet
Price: $63.44 --0%
Financial Fact:
Cost of product revenues: 44.08M
Today's EPS Names:
VAXX, NMRD, AFIB, More
Financial Fact:
Cost of product revenues: 44.08M
Today's EPS Names:
VAXX, NMRD, AFIB, More
Join SI Premium – FREE
Genomic Health, Inc. (NASDAQ: GHDX) reported Q4 EPS of $0.08, $0.02 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $53.4 million versus the consensus estimate of $53.83 million.
Genomic Health, Inc. sees FY2012 revenue of $230-$240 million, versus the consensus of $236.28 million.
For earnings history and earnings-related data on Genomic Health, Inc. (GHDX) click here.
Genomic Health, Inc. sees FY2012 revenue of $230-$240 million, versus the consensus of $236.28 million.
For earnings history and earnings-related data on Genomic Health, Inc. (GHDX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stratasys (SSYS) Tops Q2 EPS by 2c ;; Offers Guidance
- Buda Juice, Inc. (BUDA) Reports Q2 EPS of $0.04
- Beyond Air, Inc. (XAIR) Tops Q1 reported Q1 Revenue ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
